CClinicalTrials.gg
Status unknownNCT03467672SEPSISEOUpdated May 1, 2019

Interest of Eosinopia in the Diagnosis of Infection in the Emergency Department

An observational study in Eosinopenia, sponsored by University Hospital, Strasbourg, France. Status unknown at 6 sites in France. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2019-05-01.

Sponsored by University Hospital, Strasbourg, France · Observational

The sponsor has not verified this record recently (last verified Apr 2019), so the status shown — last known as Recruiting — may be out of date.
Study type
Observational
Model
Case-control
Time perspective
Prospective
Enrollment
2,000
Ages
18 Years and older
Sex
All
01

Study summary

Several studies have described the interest of eosinopenia as a marker of infection in internal medicine or in intensive care units. Eosinopenia is an inexpensive and easily accessible biological marker of sepsis. Retrospective work in the adult emergency departments of Strasbourg University Hospitals has shown the good specificity of this biological sign for the diagnosis of infection. Our work aims to confirm the results by a more meaningful study.

Main objective: Evaluation of the interest of eosinopenia in the diagnosis of bacterial infection in ED.

Methodology: inclusion of all patients with criteria for bacterial infection in ED, inclusion of an equivalent number of uninfected control patients.

Duration : 12 months Multicentric prospective study 6 centers : Strasbourg, Hôpital Nord Franche comté, Sélestat, Wissembourg, Colmar, Mulhouse

02

Conditions studied

  • Eosinopenia

Browse trials for

03

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

Any adult emergency counseling subjects who benefit from the routine practice of NFS for any indication.

Inclusion criteria

  • major patient
  • patient suspected of infection and benefiting from the routine practice of NFS, whatever the indication during his / her visit to the emergency room.
  • patient with or without criteria for bacterial infection
  • patient affiliated to a social security scheme
  • patient (or legal representative) who has agreed to participate in the study

Exclusion criteria

Exclusion Criteria:

  • anti tumor chemotherapy
  • immunosuppressive treatment
  • corticotherapy
  • antibiotherapy in progress
  • malignant hemopathy
  • evolutionary cancer
  • refusal to participate in the study
  • subjects under safeguard of justice
  • subject under guardianship or curatorship
04

Study design

Observational model
Case-control
Time perspective
Prospective
Enrollment
2,000 participants (estimated)
Patient registry
No

Groups and cohorts

  • Infected patients

    Other: Diagnosis of bacterial infection

  • Control group

    Other: Diagnosis of bacterial infection

Interventions

  • OtherDiagnosis of bacterial infection

    use of eosinopenia in the diagnosis of bacterial infection

05

What researchers measure

Primary outcomes

  1. eosinopenia as a sepsis marker

    Evaluation of the interest of eosinopenia in the diagnosis of infectious states in emergencies.

    Time frame: 102 month

06

Study locations

6 of 6 sites recruiting
07

References and documents

Individual participant data

Plan to share: Undecided

No publications or documents are linked to this record.

08

Registry details

Key details

Study ID
NCT03467672
Lead sponsor
University Hospital, Strasbourg, France
Responsible party
Sponsor
First posted
Mar 16, 2018
Start date
Mar 23, 2018
Primary completion
Mar 2020 (estimated)
Completion
Mar 2020 (estimated)
Last update
May 1, 2019

Study contacts

Charles-Eric Dr. LAVOIGNET
Contact
Charles-eric.lavoignet@hnfc.fr
03 84 98 33 97
Pascal BILBAULT
Contact
Pascal.Bilbault@chru-strasbourg.fr
03 88 12 86 82

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is status unknown, as verified in Apr 2019. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion